GlaxoSmithKline (GSK) and Pfizer are merging their consumer healthcare businesses.
The two companies’ over-the-counter/consumer healthcare units generated a combined $12.7 billion in sales last year. After the all-equity merger, GSK will own 68% of the joint venture, while Pfizer will hold the rest. The deal is expected to close in the second half of 2019.
Following the merger, GSK plans to spin off the consumer healthcare segment and list it on a London stock exchange within three years, as it plans to focus more on its pharma business. Expecting to save 500 million pounds (about $632 million) by 2022 from the deal, GSK plans to reinvest up to 25 percent of the cost savings into the company's innovation efforts.
For Pfizer, too, the deal should allow more room for the company to concentrate on its prescription drug business from which it makes most of its revenues.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PFE advanced for three days, in of 275 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on July 01, 2025. You may want to consider a long position or call options on PFE as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for PFE just turned positive on July 01, 2025. Looking at past instances where PFE's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 213 cases where PFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
PFE broke above its upper Bollinger Band on July 01, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.763) is normal, around the industry mean (5.632). P/E Ratio (74.919) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.281) is also within normal values, averaging (3.004). Dividend Yield (0.060) settles around the average of (0.161) among similar stocks. P/S Ratio (2.674) is also within normal values, averaging (3.643).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of vaccines and injectable biologic medicines
Industry PharmaceuticalsMajor